Article
Oncology
Zhenyu Yang, Yuchao Ni, Diwei Zhao, Yijun Zhang, Jun Wang, Lijuan Jiang, Dong Chen, Zhiming Wu, Yanjun Wang, Liru He, Yanxia Shi, Fangjian Zhou, Hao Zeng, Yonghong Li
Summary: The study showed that a corticosteroid switch from prednisone to dexamethasone is effective for mCRPC patients who progressed on A + P treatment. Patients with lower PSA levels at corticosteroid switch and/or longer mCRPC-free survival may benefit more from the corticosteroid switch.
Article
Oncology
Axel S. Merseburger, Gerhardt Attard, Lennart astroem, Vsevolod B. Matveev, Sergio Bracarda, Adil Esen, Susan Feyerabend, Elzbieta Senkus, Marta Lopez-Brea Piqueras, Gunther Boysen, Georgia Gourgioti, Karla Martins, Simon Chowdhury
Summary: The study found that continuing enzalutamide with docetaxel and androgen deprivation therapy can delay progression in men with mCRPC, supporting the idea that enzalutamide maintenance may control persistent androgen-dependent clones.
Review
Oncology
Xingyu Xiong, Shi Qiu, Xianyanling Yi, Hang Xu, Dazhou Liao, Haoran Lei, Shengjiang Bai, Ge Peng, Jianzhong Ai, Lu Yang
Summary: The systematic review suggests that switching from prednisone to dexamethasone in patients with metastatic castration-resistant prostate cancer after progression on abiraterone acetate plus prednisone may be an effective and safe treatment strategy. Positive rates of PSA50 and PSA30 were observed on abiraterone acetate plus dexamethasone, with good tolerability among patients.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2021)
Article
Oncology
Mark C. Markowski, Ronald Tutrone, Christopher Pieczonka, K. Gary Barnette, Robert H. Getzenberg, Domingo Rodriguez, Mitchell S. Steiner, Daniel R. Saltzstein, Mario A. Eisenberger, Emmanuel S. Antonarakis
Summary: The clinical trial demonstrated that chronic oral daily dosing of sabizabulin has a favorable safety profile with preliminary antitumor activity.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Jimmy L. Zhao, Emmanuel S. Antonarakis, Heather H. Cheng, Daniel J. George, Rahul Aggarwal, Elyn Riedel, Takayuki Sumiyoshi, Joseph D. Schonhoft, Amanda Anderson, Ninghui Mao, Samuel Haywood, Brooke Decker, Tracy Curley, Wassim Abida, Felix Y. Feng, Karen Knudsen, Brett Carver, Mario E. Lacouture, Alexander W. Wyatt, Dana Rathkopf
Summary: CC-115, a dual mTORC1/2 and DNA-PK inhibitor, showed promising antitumour activity in combination with androgen receptor (AR) inhibition in pre-clinical models. In a phase 1b trial, the combination of enzalutamide and CC-115 was well tolerated and resulted in significant reduction in PSA levels. However, CC-115 may not be sufficient to inhibit DNA-PK at the recommended phase 2 dose (RP2D). Potential predictive biomarkers of response to a PI3K/AKT/mTOR pathway inhibitor were identified.
BRITISH JOURNAL OF CANCER
(2023)
Article
Oncology
Ronald de Wit, Stephen J. Freedland, Stephane Oudard, Georgi Marinov, Philippe Capart, Austin J. Combest, Ryan Peterson, Ayse Ozatilgan, Alicia K. Morgans
Summary: This study compared the characteristics and treatment patterns of real-world prostate cancer patients with those of the population in the CARD study, and found that the treatment responses were similar in both populations.
PROSTATE CANCER AND PROSTATIC DISEASES
(2023)
Article
Endocrinology & Metabolism
Pierre-Gilles Vestris, Gilles Gourtaud, Cedric Senechal, Yvanne Sadreux, Virginie Roux, Pascal Blanchet, Laurent Brureau
Summary: The study aimed to evaluate the overall and progression-free survival of African ancestry men with mCRPC treated with docetaxel, abiraterone, or enzalutamide. The results suggest the potential benefit of hormonotherapy, particularly abiraterone, as first-line treatment for mCRPC patients of African ancestry.
Article
Oncology
David Pook, Daniel M. Geynisman, Joan Carles, Filippo de Braud, Anthony M. Joshua, Jose Luis Perez-Gracia, Casilda Llacer Perez, Sang Joon Shin, Bruno Fang, Minal Barve, Marco Maruzzo, Sergio Bracarda, Miso Kim, Yannick Kerloeguen, Jorge Daniel Gallo, Sophia L. Maund, Adam Harris, Kuan-Chieh Huang, Victor Poon, Dhruvitkumar S. Sutaria, Howard Gurney
Summary: The combination of ipatasertib and rucaparib showed manageable safety in patients with metastatic castration-resistant prostate cancer, but did not demonstrate synergistic or additive antitumor activity in previously treated patients.
CLINICAL CANCER RESEARCH
(2023)
Article
Multidisciplinary Sciences
Yuji Hakozaki, Yuta Yamada, Yuta Takeshima, Satoru Taguchi, Taketo Kawai, Masaki Nakamura, Takuya Iwaki, Taro Teshima, Yoshitaka Kinoshita, Yoshiyuki Akiyama, Yusuke Sato, Daisuke Yamada, Motofumi Suzuki, Haruki Kume
Summary: The study aimed to identify prognostic factors in metastatic castration-resistant prostate cancer (mCRPC) patients and propose a new risk model. Clinical data of 102 mCRPC patients who received treatment between 2005 and 2018 at the University of Tokyo Hospital were retrospectively analyzed. The study found that low hemoglobin levels, short time to nadir PSA, and rapid PSA doubling time were independent prognostic factors for overall survival (OS).
SCIENTIFIC REPORTS
(2023)
Review
Biochemistry & Molecular Biology
Ivan Henriquez, Mack I. I. I. I. I. I. Roach, Todd M. Morgan, Alberto Bossi, Junior A. Gomez, Oscar Abuchaibe, Felipe Counago
Summary: mCRPC is a complex disease with a wide range of molecular tumor behavior and high risk of progression, making early detection and treatment crucial. Treatment options have improved significantly in recent years, but clinicians find it challenging to keep up with the rapidly changing therapeutic landscape.
Article
Urology & Nephrology
Evan Y. Yu, Michael P. Kolinsky, William R. Berry, Margitta Retz, Loic Mourey, Josep M. Piulats, Leonard J. Appleman, Emanuela Romano, Gwenaelle Gravis, Howard Gurney, Martin Bogemann, Urban Emmenegger, Anthony M. Joshua, Mark Linch, Srikala Sridhar, Henry J. Conter, Brigitte Laguerre, Christophe Massard, Xin Tong Li, Charles Schloss, Christian H. Poehlein, Johann S. de Bono
Summary: The study evaluated the efficacy and safety of pembrolizumab combined with docetaxel and prednisone in patients with mCRPC, showing promising antitumor activity and manageable safety in this patient population.
Article
Oncology
Jun Li, Nan Liu, Hong Zhou, Peng Xian, Yanping Song, Xianli Tang, Yuan Li, Michael Basler
Summary: This study found that immunoproteasome inhibition has a significant effect on suppressing the progression of castration-resistant prostate cancer (CRPC). The results showed that immunoproteasome inhibition prevents CRPC progression by suppressing inflammation and inducing apoptosis of CRPC cells through activating the unfolded protein response.
BRITISH JOURNAL OF CANCER
(2023)
Article
Medical Laboratory Technology
Maibritt Norgaard, Marianne T. Bjerre, Jacob Fredsoe, Soren Vang, Jorgen B. Jensen, Bram De Laere, Henrik Groenberg, Michael Borre, Johan Lindberg, Karina D. Sorensen
Summary: The clinical utility of low-pass whole-genome sequencing (LPWGS) of circulating tumor DNA (ctDNA) for prognostication in metastatic castration-resistant prostate cancer (mCRPC) was examined. The study found that high ctDNA% and high copy number alteration (CNA) burden at baseline were associated with poor treatment response, progression-free survival (PFS), and overall survival (OS). These findings were confirmed in an independent cohort.
CLINICAL CHEMISTRY
(2023)
Article
Oncology
Aurelius Omlin, Richard Cathomas, Gunhild von Amsberg, Christoph Reuter, Susan Feyerabend, Wolfgang Loidl, Martin Boegemann, Anja Lorch, Axel Heidenreich, Igor Tsaur, Julian Larcher-Senn, Stefan A. J. Buck, Ron H. J. Mathijssen, Ulrich Jaehde, Silke Gillessen, Markus Joerger
Summary: This study compares the efficacy of cabazitaxel at different doses in patients with metastatic castration-resistant prostate cancer (mCRPC) and finds that individual dose adjustments of cabazitaxel can improve clinical feasibility and survival outcome in patients.
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Christopher J. Sweeney, Ivor J. Percent, Sunil Babu, Jennifer L. Cultrera, Bryan A. Mehlhaff, Oscar B. Goodman, David S. Morris, Ian D. Schnadig, Costantine Albany, Neal D. Shore, Paul R. Sieber, Susan C. Guba, Wei Zhang, Volker Wacheck, Gregory P. Donoho, Anna M. Szpurka, Sophie Callies, Boris Kin Lin, Johanna C. Bendell
Summary: In patients with metastatic castration-resistant prostate cancer (mCRPC) who had progressed on abiraterone treatment, the combination of samotolisib/enzalutamide showed tolerable side effects and significantly improved progression-free survival (PFS), especially in patients with intact PTEN and no androgen receptor splice variant 7.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Sandra van Wilpe, Shabaz Sultan, Mark A. J. Gorris, Diederik M. Somford, Heidi V. N. Kusters-Vandevelde, Rutger H. T. Koornstra, Winald R. Gerritsen, Michiel Simons, Antoine G. van der Heijden, I. Jolanda M. de Vries, Niven Mehra
Summary: The aim of this study was to improve our understanding of the immune-modulating effects of neoadjuvant cisplatin-based chemotherapy (NAC) in muscle-invasive bladder cancer (MIBC) patients. We found a decrease in intratumoral CD3(+) T cell density following NAC in MIBC patients with an early recurrence.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2023)
Article
Oncology
Maarten J. van der Doelen, Irma M. Oving, Dirk N. J. Wyndaele, Jean-Paul van Basten, Frederiek Terheggen, Addy C. M. van de Luijtgaarden, Wim J. G. Oyen, W. Dick van Schelven, Franchette van den Berkmortel, Niven Mehra, Marcel J. R. Janssen, Judith B. Prins, Winald R. Gerritsen, Jose A. E. Custers, Inge M. van Oort
Summary: This study evaluated the health-related quality of life, psychological distress, and fatigue in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223. The study found that patients who discontinued radium-223 therapy had worse HR-QoL, psychological distress, and fatigue at baseline and more frequent deterioration over time compared to patients who completed therapy.
PROSTATE CANCER AND PROSTATIC DISEASES
(2023)
Article
Hospitality, Leisure, Sport & Tourism
Rafael Suarez-Vega, Jorge Perez-Rodriguez, Juan M. Hernandez
Summary: This paper analyzes the substitution of P2P accommodation for traditional accommodation and the impact of the COVID-19 pandemic on demand and substitution effects, considering dynamic and spatial spillover effects. The results show that there is a significant substitution effect between P2P accommodation and hotels in the short term, and this substitution effect and consumer sensitivity to prices and substitution increase in the long term. However, the outbreak of COVID-19 has largely distorted the price and income elasticities.
CURRENT ISSUES IN TOURISM
(2023)
Article
Economics
Jorge Perez-Rodriguez, Juan M. Hernandez
Summary: This paper analyzes the impact of hosts' professionalism and accommodation types on the time-varying technical efficiency of P2P accommodation using a panel data stochastic frontier model. The results show that the lowest priced lodgings are the most efficient and properties managed by single-unit hosts are more efficient than those managed by multi-unit hosts.
Article
Oncology
Kim N. Chi, Alan Barnicle, Caroline Sibilla, Zhongwu Lai, Claire Corcoran, J. Carl Barrett, Carrie A. Adelman, Ping Qiu, Ashley Easter, Simon Dearden, Geoffrey R. Oxnard, Neeraj Agarwal, Arun Azad, Johann de Bono, Joaquin Mateo, David Olmos, Antoine Thiery-Vuillemin, Elizabeth A. Harrington
Summary: This study evaluated the utility of plasma-derived circulating tumor DNA (ctDNA) in identifying BRCA1, BRCA2, and ATM alterations in patients with metastatic castration-resistant prostate cancer. The results showed that ctDNA detection can complement tissue testing and serve as a valuable alternative for patients with no or insufficient tissue for genomic analyses.
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Nobuaki Matsubara, Johann de Bono, David Olmos, Giuseppe Procopio, Satoru Kawakami, Yuksel Urun, Robbert van Alphen, Aude Flechon, Michael A. Carducci, Young Deuk Choi, Sebastien J. Hotte, Ernesto Korbenfeld, Gero Kramer, Neeraj Agarwal, Kim N. Chi, Simon Dearden, Christopher Gresty, Jinyu Kang, Christian Poehlein, Elizabeth A. Harrington, Maha Hussain
Summary: The purpose of this study was to evaluate the use of ctDNA testing as an alternative method to identify mCRPC patients with HRR gene alterations who may benefit from olaparib treatment. The results showed that ctDNA testing can be a suitable alternative when tissue testing is not feasible or has failed.
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
YaoYao Pollock, Matthew R. Smith, Fred Saad, Simon Chowdhury, Stephane Oudard, Boris Hadaschik, David Olmos, Ji Youl Lee, Hiroji Uemura, Amitabha Bhaumik, Anil Londhe, Brendan Rooney, Sabine D. Brookman-May, Peter De Porre, Suneel D. Mundle, Eric J. Small
Summary: This study analyzed the risk factors for falls in patients with non-metastatic castration-resistant prostate cancer treated with apalutamide and suggested that clinical management can minimize these risks and improve patient outcomes.
PROSTATE CANCER AND PROSTATIC DISEASES
(2023)
Article
Medical Laboratory Technology
Juan M. Jimenez-Vacas, Antonio J. Montero-Hidalgo, Enrique Gomez-Gomez, Prudencio Saez-Martinez, Antonio C. Fuentes-Fayos, Adria Closa, Teresa Gonzalez-Serrano, Ana Martinez-Lopez, Rafael Sanchez-Sanchez, Pedro P. Lopez-Casas, Andre Sarmento-Cabral, David Olmos, Eduardo Eyras, Justo P. Castano, Manuel D. Gahete, Raul M. Luque
Summary: Prostate cancer is a major cause of cancer-related deaths in men, and there is a need for novel molecular targets for treatment. The study found that RB22, a key spliceosome component, is down-regulated in prostate cancer and is associated with tumor aggressiveness. Overexpression of RB22 can reduce the aggressiveness of prostate cancer by impacting the splicing of numerous genes and the regulation of cell cycle. Targeting negative regulators of RB22 expression/activity could be a novel therapeutic strategy for prostate cancer.
TRANSLATIONAL RESEARCH
(2023)
Article
Oncology
Z. Kuzbari, C. Bandlamudi, C. Loveday, A. Garrett, M. Mehine, A. George, H. Hanson, K. Snape, A. Kulkarni, S. Allen, S. Jezdic, R. Ferrandino, C. B. Westphalen, E. Castro, J. Rodon, J. Mateo, G. J. Burghel, M. F. Berger, D. Mandelker, C. Turnbull
Summary: The ESMO PMWG updated their recommendations on follow-up of putative germline variants detected on tumour-only sequencing, based on an analysis of an expanded dataset including 49,264 paired tumour-normal samples. They applied filters to tumour-detected variants and found that a subset of these variants can produce actionable true germline variants. They have revised the guidelines and included new genes for germline follow-up.
ANNALS OF ONCOLOGY
(2023)
Article
Oncology
Yanin Chavarri-Guerra, Maria T. Bourlon, Jose L. Rodriguez-Olivares, Luis Orozco, Deborah Bazua, Andres Rodriguez-Faure, Mirza J. Alcalde-Castro, Elena Castro, Danielle Castillo, Josef Herzog, Jeffrey Weitzel
Summary: We conducted a study on the frequency of DNA repair gene pathogenic variants among Mexican men with prostate cancer and found a low prevalence of these variants, indicating that the genetic and/or epidemiologic risk factors for prostate cancer are not well characterized in this population.
CLINICAL GENITOURINARY CANCER
(2023)
Article
Oncology
Rebeca Lozano, Elena Castro, Fernando Lopez -Campos, Heather Thorne, Miguel Ramirez-Backhaus, Isabel M. Aragon, Ylenia Cendon-Florez, Ana Gutierrez-Pecharroman, Daniela C. Salles, Nuria Romero-Laorden, David Lorente, Pilar Gonzalez-Peramato, Ana Calatrava, Concepcion Alonso, Urbano Anido, Sara Arevalo-Lobera, Judith Balmana, Isabel Chirivella, Maria Jose Juan-Fita, Gemma Llort, Teresa Ramon Y. Cajal, Elena Almagro, Daniel Alameda, Pedro P. Lopez-Casas, Bernardo Herrera, Joaquin Mateo, Colin C. Pritchard, Emmanuel S. Antonarakis, Tamara L. Lotan, Jose Rubio-Briones, Shahneen Sandhu, David Olmos
Summary: This study found that germline BRCA2 mutations are associated with poor clinical outcomes in prostate cancer patients, and the concurrent somatic events of BRCA2-RB1 co-deletion and MYC amplification are enriched in these tumors. The presence or absence of these events modifies the clinical outcomes of gBRCA2 carriers.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Peter H. J. Slootbeek, Joanneke K. Overbeek, Marjolijn J. L. Ligtenberg, Nielka P. van Erp, Niven Mehra
Summary: PARP inhibitors have shown great potential in the treatment of metastatic castration-resistant prostate cancer, with superior responses observed in patients with BRCA1 or BRCA2 gene mutations. Combination therapy with androgen receptor signaling inhibitors can prolong progression-free survival in HRRm patients, but has limited efficacy in the non-HRRm subgroup.
Review
Pharmacology & Pharmacy
Eva Podgorsek, Niven Mehra, Inge M. M. van Oort, Diederik M. M. Somford, Emmy Boerrigter, Nielka P. P. van Erp
Summary: Darolutamide is a next-generation androgen receptor signaling inhibitor (ARSI) approved for the treatment of nonmetastatic castration-resistant prostate cancer (nmCRPC) and metastatic hormone sensitive prostate cancer (mHSPC). It has the potential to be used in other stages of prostate cancer (PC) as well. Pharmacokinetic properties and patient characteristics can help physicians decide the choice of ARSIs.
CLINICAL PHARMACOKINETICS
(2023)
Article
Urology & Nephrology
Niven Mehra, Iris Kloots, Michiel Vlaming, Shafak Aluwini, Els Dewulf, Daniela E. Oprea-Lager, Henk van der Poel, Herman Stoevelaar, Derya Yakar, Chris H. Bangma, Elise Bekers, Roderick van den Bergh, Andries M. Bergman, Franchette van den Berkmortel, Steve Boudewijns, Winand N. M. Dinjens, Jurgen Futterer, Tom van der Hulle, Guido Jenster, Leonie I. Kroeze, Michel van Kruchten, Geert van Leenders, Pim J. van Leeuwen, Wendy W. J. de Leng, R. Jeroen A. van Moorselaar, Walter Noordzij, Rogier A. Oldenburg, Inge M. van Oort, Irma Oving, Jack A. Schalken, Ivo G. Schoots, Ed Schuuring, Robert J. Smeenk, Ben G. L. Vanneste, Erik Vegt, Andre N. Vis, Kim de Vries, Peter-Paul M. Willemse, Maurits Wondergem, Margreet Ausems
Summary: A group of Dutch specialists discussed the use of germline and tumour genetic testing in prostate cancer (PCa) patients, indication of these tests (which patients and when), and impact of these tests on the management and treatment of PCa.
EUROPEAN UROLOGY OPEN SCIENCE
(2023)